Shamburg News · 8-K filed Oct 23, 2026, 9:00 AM EDT

Tempus AI Signs Data and Tool Agreements with Bristol-Myers Squibb and Pathos AI Worth Up to $192.5 Million

TEM · Tempus AI, Inc.

  • Material agreement
  • Other event
  • Materiality: medium

On October 23, 2026, Tempus AI, Inc. announced agreements with Bristol-Myers Squibb and Pathos AI to expand licensing of its de-identified real-world data, analysis software, and agentic tools. The Onco SOW provides for $137.5 million in fixed payments from BMS through December 31, 2031, and the Neuro Order Form provides for up to $55 million in cash from Pathos over five years. The Neuro Order Form and Side Letter were approved by a special committee of disinterested directors under Tempus's Related Person Transaction Policy.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 8.01, accession 0001193125-26-429533.

Written from the filing by Shamburg Markets. Figures are as reported by the company.